Minerva Neurosciences, Inc. Stock Price

NasdaqCM:NERV Community·US$26.6m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
1 Fair Values set on narratives written by author

Create a narrative

NERV Share Price Performance

US$3.80

1.61 (73.52%)

US$3.80

1.61 (73.52%)

US$3.80

Thu, 18 Dec 25

Share Pricen/a

NERV Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Trending Discussion

Snowflake Analysis

Moderate risk with imperfect balance sheet.

5 Risks

0 Rewards

View Full Analysis

Minerva Neurosciences, Inc. Key Details

Last Reported Earnings

Sep 30, 2025

Next Reporting Earnings

n/a

: -2.01
: 0%
: 0%
: -173.5%

View Full Analysis

About NERV

Founded: 2007
Employees: 8
CEO: Remy Luthringer
WebsiteView website: www.minervaneurosciences.com

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson’s disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.